The Promise of Peptide Therapeutics

Welcome to Protagonist, a clinical-stage biopharmaceutical company poised to deliver life-changing therapies

Learn More

Learn more about a clinical study (the VERIFY study) which uses an investigational study drug called rusfertide, also known as PTG-300, for the treatment of polycythemia vera:

Advancing Important Drug Candidates
into the Clinic

At Protagonist, we strive to improve patients’ lives through the power of drug discovery and development, targeting areas of unmet need across rare and prevalent diseases where treatments are limited or inadequate. Today, we have two drug candidates in late-stage development: rusfertide and PN-235 (JNJ-2113).

Learn More
A scientist typing at their computer surrounded by beakers and medicine

Corporate Presentation